Clinical Trial Update: A Study to Compare the PK , Safety, and Immunogenicity of QL2109 With Daratumumab in Male Subjects [Phase 1]

View source ↗

Summary

Phase 1 clinical trial to compare pharmacokinetics, safety, and immunogenicity of QL2109 with daratumumab in male subjects with multiple myeloma; not yet recrui…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Daratumumab (daratumumab)
• QL2109 (daratumumab biosimilar)

Snippet

Sponsor: Qilu Pharmaceutical Co., Ltd. | Conditions: Multiple Myeloma | Phase 1 | Status: NOT_YET_RECRUITING